Suvretta Capital Management 13F holdings, Q1 2022
Holdings as of March 31, 2022 · filings on SEC EDGAR · latest filing →
Suvretta Capital Management disclosed 87 US equity positions worth $3.3bn in its Q1 2022 13F filing. The largest position was MSFT at 5.6% of the reported book, followed by UNP and AMZN. Against the Q4 2021 filing, it opened 13 new positions, added to 15 and reduced 18 among the top 50 holdings.
What did Suvretta Capital Management own in Q1 2022? Top 50 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q4 2021 |
|---|---|---|---|---|---|---|---|
| 1 | MSFT MICROSOFT CORP | Technology | 5.6% | $183.7m | 595,747 | -31% | reduced |
| 2 | UNP UNION PAC CORP | Industrials | 5.1% | $167.6m | 613,628 | -24% | reduced |
| 3 | AMZN AMAZON COM INC | Consumer Cyclical | 4.5% | $147.1m | 45,122 | -58% | reduced |
| 4 | UNH UNITEDHEALTH GROUP INC | Healthcare | 3.8% | $122.9m | 240,997 | -47% | reduced |
| 5 | EL LAUDER ESTEE COS INC | Consumer Defensive | 3.1% | $101.4m | 372,475 | -17% | reduced |
| 6 | CNC CENTENE CORP DEL | Healthcare | 3.1% | $100.8m | 1,197,206 | – | new |
| 7 | OTIS OTIS WORLDWIDE CORP | Industrials | 3.0% | $99.8m | 1,297,480 | -48% | reduced |
| 8 | V VISA INC | Financial Services | 3.0% | $97.1m | 437,990 | – | new |
| 9 | INTRA-CELLULAR THERAPIES INC | 2.9% | $93.7m | 1,531,923 | 22% | added | |
| 10 | IQV IQVIA HLDGS INC | Healthcare | 2.7% | $89.4m | 386,710 | -31% | reduced |
| 11 | LVS LAS VEGAS SANDS CORP | Consumer Cyclical | 2.7% | $88.4m | 2,275,282 | – | new |
| 12 | TPR TAPESTRY INC | Consumer Cyclical | 2.6% | $86.2m | 2,320,100 | -49% | reduced |
| 13 | SPGI S&P GLOBAL INC | Financial Services | 2.6% | $84.8m | 206,760 | – | new |
| 14 | SCHW SCHWAB CHARLES CORP | Financial Services | 2.5% | $82.9m | 982,790 | – | new |
| 15 | HUM HUMANA INC | Healthcare | 2.5% | $82.2m | 188,888 | – | new |
| 16 | RPRX ROYALTY PHARMA PLC | Healthcare | 2.4% | $78.9m | 2,025,610 | 3% | added |
| 17 | GFL GFL ENVIRONMENTAL INC | Industrials | 2.3% | $74.3m | 2,284,496 | -51% | reduced |
| 18 | JNJ JOHNSON & JOHNSON | Healthcare | 2.2% | $73.6m | 415,310 | – | new |
| 19 | MA MASTERCARD INCORPORATED | Financial Services | 2.1% | $68.2m | 190,943 | -24% | reduced |
| 20 | DHR DANAHER CORPORATION | Healthcare | 2.1% | $68.2m | 232,570 | 6% | added |
| 21 | TMO THERMO FISHER SCIENTIFIC INC | Healthcare | 2.1% | $68.0m | 115,069 | -57% | reduced |
| 22 | KURA KURA ONCOLOGY INC | Healthcare | 1.9% | $62.6m | 3,893,019 | 9% | added |
| 23 | FULC FULCRUM THERAPEUTICS INC | Healthcare | 1.9% | $61.8m | 2,613,412 | 10% | added |
| 24 | RH RH | Consumer Cyclical | 1.8% | $59.3m | 181,835 | -27% | reduced |
| 25 | COR AMERISOURCEBERGEN CORP | Healthcare | 1.8% | $59.3m | 383,138 | -69% | reduced |
| 26 | HLT HILTON WORLDWIDE HLDGS INC | Consumer Cyclical | 1.7% | $55.0m | 362,703 | -39% | reduced |
| 27 | MAR MARRIOTT INTL INC NEW | Consumer Cyclical | 1.7% | $54.3m | 309,240 | -37% | reduced |
| 28 | XLE SELECT SECTOR SPDR TR | 1.6% | $53.0m | 692,868 | – | new | |
| 29 | BBWI BATH & BODY WORKS INC | Consumer Cyclical | 1.5% | $49.6m | 1,038,630 | – | new |
| 30 | MQ MARQETA INC | Technology | 1.4% | $44.7m | 4,049,950 | 176% | added |
| 31 | MIRATI THERAPEUTICS INC | 1.3% | $42.0m | 510,331 | 27% | added | |
| 32 | DECK DECKERS OUTDOOR CORP | Consumer Cyclical | 1.2% | $39.0m | 142,477 | -34% | reduced |
| 33 | RARE ULTRAGENYX PHARMACEUTICAL IN | Healthcare | 1.2% | $38.1m | 525,100 | 8% | added |
| 34 | EYPT EYEPOINT PHARMACEUTICALS INC | Healthcare | 1.1% | $35.3m | 2,909,407 | 15% | added |
| 35 | AGIO AGIOS PHARMACEUTICALS INC | Healthcare | 1.0% | $34.3m | 1,177,374 | 0% | held |
| 36 | INSM INSMED INC | Healthcare | 0.9% | $31.0m | 1,318,432 | 22% | added |
| 37 | STRO SUTRO BIOPHARMA INC | Healthcare | 0.9% | $30.7m | 3,732,400 | 53% | added |
| 38 | MCK MCKESSON CORP | Healthcare | 0.9% | $30.0m | 97,980 | – | new |
| 39 | WYNN WYNN RESORTS LTD | Consumer Cyclical | 0.9% | $29.2m | 366,060 | – | new |
| 40 | MARINUS PHARMACEUTICALS INC | 0.8% | $25.9m | 2,766,000 | 5% | added | |
| 41 | 4XC1 KALVISTA PHARMACEUTICALS INC | 0.8% | $25.7m | 1,746,300 | 0% | held | |
| 42 | POINT BIOPHARMA GLOBAL INC | 0.7% | $24.0m | 3,014,408 | 13% | added | |
| 43 | NTRA NATERA INC | Healthcare | 0.7% | $23.8m | 584,660 | -8% | reduced |
| 44 | 290A CHINOOK THERAPEUTICS INC | 0.7% | $23.5m | 1,434,200 | 15% | added | |
| 45 | KEZAR LIFE SCIENCES INC | 0.7% | $23.4m | 1,409,956 | 0% | held | |
| 46 | CANO HEALTH INC | 0.7% | $23.3m | 3,668,478 | -63% | reduced | |
| 47 | XOP SPDR SER TR | 0.7% | $22.2m | 164,970 | – | new | |
| 48 | ARCELLX INC | 0.7% | $21.5m | 1,533,059 | – | new | |
| 49 | XENE XENON PHARMACEUTICALS INC | Healthcare | 0.6% | $21.2m | 692,000 | 0% | held |
| 50 | HRTX HERON THERAPEUTICS INC | Healthcare | 0.5% | $16.4m | 2,869,048 | 15% | added |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.